Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duloxetine + escitalopram is a combination of two antidepressant medications, each with distinct mechanisms of action. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI), while escitalopram is a selective serotonin reuptake inhibitor (SSRI). Both drugs increase the levels of serotonin in the brain, but duloxetine also increases norepinephrine. This combination may be considered in treatment-resistant cases of major depressive disorder or other psychiatric conditions where monotherapy has been insufficient. However, combining these agents significantly increases the risk for serotonin syndrome—a potentially life-threatening condition due to excessive serotonergic activity[1][3]. There are limited clinical studies on this specific combination; most evidence comes from case reports and small observational studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on duloxetine + escitalopram.